Media coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.5905108200107 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s rankings:
- Grifols SA, Barcelona (GRFS) Upgraded to “Hold” by Zacks Investment Research (americanbankingnews.com)
- ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) Executes Definitive Agreement with DxEconomix to Lead Value-Based Transactions (investorideas.com)
- First Week of August 17th Options Trading For Grifols SA – Nasdaq (nasdaq.com)
- Stocks With Rising Relative Price Strength: Grifols (finance.yahoo.com)
- Grifols SA, Barcelona (GRFS) versus Trillium Therapeutics (TRIL) Financial Comparison (americanbankingnews.com)
Shares of Grifols SA, Barcelona (NASDAQ GRFS) opened at $23.98 on Friday. The company has a quick ratio of 1.39, a current ratio of 3.17 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $6,140.00, a P/E ratio of 25.78, a P/E/G ratio of 1.57 and a beta of 1.03. Grifols SA, Barcelona has a twelve month low of $16.37 and a twelve month high of $24.20.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-grifols-sa-barcelona-grfs-stock-price.html.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
What are top analysts saying about Grifols SA Barcelona? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols SA Barcelona and related companies.